## Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## 1. (Currently amended): A compound of formula (I)

wherein:

Z<sub>1</sub> is N <del>or CR<sup>1a</sup></del>;

R1 and R1a are independently hydrogen; hydroxy;  $(C_{1-6})$ alkoxy unsubstituted or substituted by  $(C_{1-6})$ alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted unsubstituted or N-substituted by one or two  $(C_{1-6})$ alkyl, acyl,  $(C_{1-6})$ alkylsulphonyl, CONH2, hydroxy,  $(C_{1-6})$ alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or  $(C_{1-6})$ alkylsulphonyloxy;  $(C_{1-6})$ alkoxy-substituted $(C_{1-6})$ alkyl; halogen;  $(C_{1-6})$ alkyl;  $(C_{1-6})$ alkylthio; trifluoromethyl; trifluoromethoxy; nitro; azido; cyano; acyl; acyloxy; acylthio;  $(C_{1-6})$ alkylsulphonyl;  $(C_{1-6})$ alkylsulphoxide; arylsulphonyl; arylsulphoxide; or an amino, piperidyl, guanidino or amidino group unsubstituted or N-substituted by one or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$ alkylsulphonyl groups; or R1 and R1a may together form ethylenedioxy;

provided that when Z<sub>1</sub> is CR<sup>1a</sup> then R<sup>1</sup> is not H;

R<sup>2</sup> is H or halogen;

provided that when  $Z_1$  is N, then  $R^2$  is H;

R3 is hydrogen; halogen; hydroxy; cyano; CF3; nitro; azido; acyl; aryl; heteroaryl;  $CO_2H$ ; acyoxy; acylthio;  $(C_{1-6})$ alkyl unsubstituted or substituted by one or two  $(C_{1-6})$ alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two  $(C_{1-6})$ alkyl, acyl,  $(C_{1-6})$ alkylsulphonyl,  $CONH_2$ , hydroxy,  $(C_{1-6})$ alkylsulphonyloxy;  $(C_{1-6})$ alkoxy, arylthio, aryloxy, acylthio, acyloxy or  $(C_{1-6})$ alkylsulphonyloxy;  $(C_{1-6})$ alkoxy unsubstituted or substituted by one or two  $(C_{1-6})$ alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two  $(C_{1-6})$ alkylsulphonyl,  $(C_{1-6})$ alkylsulphonyl,  $(C_{1-6})$ alkylsulphonyl,  $(C_{1-6})$ alkylsulphonyl, acylthio, acyloxy or  $(C_{1-6})$ alkylsulphonyloxy;  $(C_{3-7})$ cycloalkyl;  $(C_{1-6})$ alkoxy-substituted $(C_{1-6})$ alkyl;  $(C_{1-6})$ alkylsulphonyl;  $(C_{1-6})$ alkylsulphonyl; or arylsulphonyl; or anylsulphoxide; or an amino, piperidyl, guanidino or amidino group unsubstituted or N-substituted by one or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$ alkylsulphonyl groups;

```
w_1 is N, C, or CR^4;

w_2 is C=O, CR^4, or CR^4R^5;

w_3 is C=O or CR^4R^5;

w_4 is N or CR^4;

w_5 is C=O or CR^4R^5;

w_6 is C=O, CR^4, or CR^4R^5;
```

or, one of W2, W3, W5 and W6  $\underline{W_2}$ ,  $\underline{W_3}$ ,  $\underline{W_5}$  and  $\underline{W_6}$  is  $CR^4R^5CR^4R^5$  and the others are defined as above;

wherein each  $R^4$  and  $R^5$  is independently hydrogen; halogen; hydroxy; cyano;  $CF_3$ ; nitro; azido; acyl; aryl; heteroaryl;  $CO_2H$ ; acyoxy; acylthio;  $(C_{1-6})$ alkyl unsubstituted or substituted by one or two  $(C_{1-6})$ alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two  $(C_{1-6})$ alkyl, acyl,  $(C_{1-6})$ alkylsulphonyl,  $CONH_2$ , hydroxy,  $(C_{1-6})$ alkylthio, heterocyclylthio, heterocyclyloxy, arylthio,


aryloxy, acylthio, acyloxy or  $(C_{1-6})$ alkylsulphonyloxy;  $(C_{1-6})$ alkoxy unsubstituted or substituted by one or two  $(C_{1-6})$ alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two  $(C_{1-6})$ alkyl, acyl,  $(C_{1-6})$ alkylsulphonyl, CONH<sub>2</sub>, hydroxy,  $(C_{1-6})$ alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or  $(C_{1-6})$ alkylsulphonyloxy;  $(C_{3-7})$ cycloalkyl;  $(C_{1-6})$ alkoxy-substituted $(C_{1-6})$ alkyl;  $(C_{1-6})$ alkylthio; trifluoromethoxy;  $(C_{1-6})$ alkylsulphonyl;  $(C_{1-6})$ alkylsulphoxide; arylsulphonyl; or arylsulphoxide; or an amino, piperidyl, guanidino or amidino group unsubstituted or N-substituted by one or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$ alkylsulphonyl groups; or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$ alkylsulphonyl groups; or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$ alkylsulphonyl groups; or two  $(C_{1-6})$ alkyl, acyl or  $(C_{1-6})$ alkylsulphonyl groups; or two  $(C_{1-6})$ a

A is  $CR^6R^7$  or C(O); B is  $CR^8R^9$  or C(O);

> wherein  $R^6$ ,  $R^7$ ,  $R^8$ , and  $R^9$  are independently hydrogen; halogen; hydroxy; cyano; CF3; nitro; azido; acyl; aryl; heteroaryl; CO2H; acyoxy; acylthio; (C<sub>1-6</sub>)alkyl unsubstituted or substituted by one or two (C<sub>1-6</sub>)alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two ( $C_{1-6}$ )alkyl, acyl, ( $C_{1-6}$ )alkylsulphonyl, CONH<sub>2</sub>, hydroxy, (C<sub>1-6</sub>)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C<sub>1-6</sub>)alkylsulphonyloxy; (C<sub>1-6</sub>)alkoxy unsubstituted or substituted by one or two (C<sub>1-6</sub>)alkoxy, hydroxy, amino, piperidyl, guanidino or amidino any of which is unsubstituted or N-substituted by one or two ( $C_{1-6}$ )alkyl, acyl, ( $C_{1-6}$ )alkylsulphonyl, CONH<sub>2</sub>, hydroxy, ( $C_{1-6}$ ) 6)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C<sub>1-6</sub>)alkylsulphonyloxy; (C<sub>3-7</sub>)cycloalkyl; (C<sub>1-6</sub>)alkoxy $substituted (C_{1-6}) alkyl; \ (C_{1-6}) alkylthio; \ trifluoromethoxy; \ (C_{1-6}) alkylsulphonyl;$ (C<sub>1-6</sub>)alkylsulphoxide; arylsulphonyl; or arylsulphoxide; or an amino, piperidyl, guanidino or amidino group unsubstituted or N-substituted by one or two (C<sub>1-6</sub>)alkyl, acyl or (C<sub>1-6</sub>)alkylsulphonyl groups;

R10 is hydrogen; aryl; heteroaryl; (C<sub>1-6</sub>)alkyl unsubstituted or substituted by one or two (C<sub>1-6</sub>)alkoxy, hydroxy, amino, piperidyl, piperazinyl, morpholino, guanidino, or amidino, any of which is unsubstituted or N-substituted by one or two aryl, heteroaryl, halogen, cyano, CF<sub>3</sub>, unsubstituted (C<sub>1-6</sub>)alkyl, acyl, (C<sub>1-6</sub>)alkylsulphonyl, arylsulphonyl, hydroxy, (C<sub>1-6</sub>)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy, or (C<sub>1-6</sub>)alkylsulphonyloxy, provided that the substitution does not lead to an unstable compound; (C<sub>1-6</sub>)alkoxy-substituted(C<sub>1-6</sub>)alkyl; hydroxy-substituted(C<sub>1-6</sub>)alkyl; (C<sub>1-6</sub>)alkylcarbonyl; (C<sub>2-6</sub>)alkenylcarbonyl; (C<sub>1-6</sub>)alkoxycarbonyl; CO<sub>2</sub>H; or CF<sub>3</sub>;

R<sup>11</sup> is a group -U-R<sup>12</sup> where R<sup>12</sup> is a substituted or unsubstituted bicyclic carbocyclic or heterocyclic ring system (A):



containing up to four heteroatoms in each ring in which at least one of rings (a) and (b) is aromatic;

 $\chi^1$  is C or N when part of an aromatic ring or CR  $^{14}$  when part of a non aromatic ring;

 $\rm X^2$  is N, NR<sup>13</sup>, O, S(O)<sub>X</sub>, CO or CR<sup>14</sup> when part of an aromatic or non-aromatic ring or may in addition be CR<sup>14</sup>R<sup>15</sup> when part of a non aromatic ring;

X<sup>3</sup> and X<sup>5</sup> are independently N or C;

 $Y^1$  is a 0 to 4 atom linker group each atom of which is independently selected from N, NR<sup>13</sup>, O, S(O)<sub>X</sub>, CO and CR<sup>14</sup> when part of an aromatic or non-aromatic ring or may additionally be CR<sup>14</sup>R<sup>15</sup> when part of a non aromatic ring,

 $Y^2$  is a 2 to 6 atom linker group, each atom of  $Y^2$  being independently selected from N, NR<sup>13</sup>, O, S(O)<sub>X</sub>, CO and CR<sup>14</sup> when part of an aromatic or non-aromatic ring or may additionally be CR<sup>14</sup>R<sup>15</sup> when part of a non aromatic ring;

each of R<sup>14</sup> and R<sup>15</sup> is independently selected from: H; (C<sub>1-4</sub>)alkylthio; halo; (C<sub>1-4</sub>)alkyl; (C<sub>2-4</sub>)alkenyl; hydroxy; hydroxy(C<sub>1-4</sub>)alkyl; mercapto(C<sub>1-4</sub>)alkyl; (C<sub>1-4</sub>)alkoxy; trifluoromethoxy; nitro; cyano; carboxy; amino or aminocarbonyl unsubstituted or substituted by (C<sub>1-4</sub>)alkyl;

each R<sup>13</sup> is independently H; trifluoromethyl;  $(C_{1-4})$ alkyl unsubstituted or substituted by hydroxy, carboxy,  $(C_{1-4})$ alkoxy,  $(C_{1-6})$ alkylthio, halo or trifluoromethyl;  $(C_{2-4})$ alkenyl; or aminocarbonyl wherein the amino group is optionally substituted  $(C_{1-4})$ alkyl;

each x is independently 0, 1 or 2; U is CO, SO<sub>2</sub>, CH<sub>2</sub>, or CR<sup>16</sup>R<sup>17</sup>;

R16 and R17 are independently selected from H; aryl; heteroaryl; (C1-6)alkyl; (C1-6)alkyl substituted by (C1-6)alkoxy, hydroxy, amino, piperidyl, piperazinyl, morpholino, guanidino, or amidino, any of which is substituted or N-substituted by one or two H, aryl, heteroaryl, halogen, cyano, CF3, (C1-6)alkyl, acyl, (C1-6)alkylsulphonyl, arylsulphonyl, hydroxy, (C1-6)alkylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy, or (C1-6)alkylsulphonyloxy, provided that the substitution does not lead to an unstable compound; (C1-6)alkoxy-substituted(C1-6)alkyl; hydroxy-substituted(C1-6)alkyl; amino-substituted(C1-6)alkyl, which is N-substituted by one or two (C1-6)alkyl, acyl, (C1-6)alkylsulphonyl, or arylsulphonyl; (C1-6)alkylcarbonyl; (C2-6)alkenylcarbonyl;

a pharmaceutically acceptable salt thereof.

(C<sub>1-6</sub>)alkoxycarbonyl; CO<sub>2</sub>H; or CF<sub>3</sub>; or

- 2. (Previously presented): A compound or salt according to claim 1, wherein  $R^1$  is F, Cl, OCH<sub>3</sub>, methyl, or SCH<sub>3</sub>.
- 3. (Previously presented): A compound or salt according to claim 1, wherein  $R^{1a}$  is H, OCH<sub>3</sub>, or OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>.

- 4. (Previously presented): A compound or salt according to claim 1, wherein  $\mathbb{R}^2$  is H or F.
- 5. (Previously presented): A compound or salt according to claim 1, wherein  $\mathbb{R}^3$  is  $\mathbb{C}$ I or  $\mathbb{F}$ .
- 6. (Currently amended): A compound or salt according to claim 1, wherein each R<sup>4</sup> is independently H, methyl, OH, COOH, NH<sub>2</sub>, OCH<sub>3</sub>, or CH<sub>2</sub>OH.
- 7. (Previously presented): A compound or salt according to claim 1, wherein  ${\sf R}^5$  is H.
- 8. (Previously presented): A compound or salt according to claim 1, wherein the group -U- is  $-CH_2-$ .
- 9. (Currently amended): A compound or salt according to claim 1, wherein R<sup>12</sup> is: benzo[1,2,5]thiadiazol-5-yl;

4H-benzo[1,4] thiazin-3-one-6-yl;

2,3-dihydro-benzo[1,4]dioxin-6-yl;

benzo[1,2,3]thiadiazol-5-yl;

3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl;

7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4] oxazin-6-yl;

2-oxo-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiazin-7-yl;

2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl;

3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl;

[1,2,3]thiadiazolo[5,4-b]pyridin-6-yl;

3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-yl;

7-chloro-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-yl; er

7-fluoro-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-yl; or

2-oxo-2,3-dihydro-1*H*-pyrido[3,4-b][1,4]thiazin-7-yl.

10. (Currently amended): A compound according to claim 1, wherein the compound is:

6-({2-[1-(6-methoxyquinolin-4-yl)piperidin-4-yl]ethylamino}methyl)-4*H*-pyrido[3,2-b][1,4]oxazin-3-one;

- 6-({2-[1-(6-methoxyquinolin-4-yl)piperidin-4-yl]ethylamino}methyl)-4*H*-pyrido[3,2-b][1,4]thiazin-3-one;
- (2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[1-(6-methoxyquinolin-4-yl)piperidin-4-yl]ethyl}amine;
- 6-({2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethylamino} methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;
- $6-({2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethylamino} methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;$
- (2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethyl}amine;
- 6-({2-[1-(3-chloro-6-methoxy-[1,5]quinolin-4-yl)phenyl] ethylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
- 6-({2-[1-(3-chloro-6-methoxy-[1,5]quinolin-4-yl)phenyl] ethylamino} methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- -{2-[1-(3-chloro-6-methoxyquinolin-4-yl)piperidin-4-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine;
- 6-({2-[1-(3-chloro-6-methoxy-[1,5]naphthyridin-4-yl)phenyl] ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;
- 6-({2-[1-(3-chloro-6-methoxy-[1,5]naphthyridin-4-yl)phenyl] ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
- {2-[1-(3-chloro-6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine;
- -6-({2-[4-(6-methoxyquinolin-4-yl)piperazin-1-yl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
- \_6 ({2-[4-(6-methoxyquinolin-4-yl)piperazin-1-yl]ethylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
- (2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[4-(6-methoxyquinolin-4-yl)piperizin-1-yl]ethyl}amine;
- 6-({2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl] ethylamino} methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;
- 6-({2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl] ethylamino} methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
- (2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[4-(6-methoxynaphthyridin-4-yl)piperizin-1-yl]ethyl}amine;
- -6-({2-[4-(3-chloro-6-methoxyquinolin-4-yl)piperazin-1-yl] ethylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;

6-({2-[4-(3-chloro-6-methoxyquinolin-4-yl)piperazin-1-yl] ethylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;

{2-[4-(3-chloro-6-methoxyquinolin-4-yl)piperazin-1-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine;

6-({2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl] ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;

6-({2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl] ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

{2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine;

6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)-3,6-dihydro-2 H pyridin-1-yl]-2-oxo-ethylamino}-methyl) -4 H pyrido[3,2-b][1,4]thiazin-3-one;

6-({2-[4-(6-methoxy-[1,5]naphthyridin-4-yl)-3,6-dihydro-2 H -pyridin-1-yl]-2-oxo-ethylamino}-methyl) -4 H -pyrido[3,2-b][1,4]thiazin-3-one;

N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

N-methyl-N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl} ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

N-methyl-N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl} ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

N-(2-{1-[3-chloro-6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl} ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

7-{[(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl) oxy] methyl}-2,3-dihydro[1,4]dioxino[2,3-c]pyridine;

N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

N-methyl-N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

N-methyl-N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl} ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

 $6-\{[(2-\{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]hexahydro-1H-1,4-diazepin-1-yl]ethyl]amino]methyl]-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;$ 

N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]hexahydro-1H-1,4-diazepin-1-yl}ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

 $6-\{[(2-\{(1R,4R)-5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2,5-diazabicyclo [2.2.1]hept-2-yl\}ethyl)amino]methyl\}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;$ 

6-[({1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}amino) methyl]-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;

 $6-\{[(2-\{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl\}ethyl)\\ amino]methyl\}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;$ 

 $6-\{[(2-\{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl\}ethyl)\\ amino]methyl\}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one;$ 

N-(2-{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl} ethyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine-6-sulfonamide;

 $6-\{[(2-\{4-[7-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl\}\ ethyl) amino]methyl\}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; \\ \underline{or}$ 

6-{[(2-{4-[7-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl} ethyl)amino]methyl}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; or a pharmaceutical pharmaceutically acceptable salt thereof.

- 11. (Previously presented): A pharmaceutical composition, comprising a compound or salt according to claim 1 and a pharmaceutically acceptable carrier.
- 12. (Previously presented): A method of treating bacterial infections in mammals, which comprises administering to a mammal in need thereof an effective amount of a compound or salt according to claim 1.
- 13. (New) A method according to claim 12, wherein the mammal is a human.
- 14. (New) A compound or salt according to claim 1, wherein  $R^{12}$  is an aromatic heterocyclic ring (A) having 8-11 ring atoms including 2-4 heteroatoms of which at least one is N or NR<sup>13</sup>, in which preferably Y<sup>2</sup> contains 2-3 heteroatoms, one of which is S and 1-2 are N, with one N bonded to  $X^3$ .
- 15. (New) A compound or salt according to claim 1, wherein  $R^{12}$  has a heterocyclic ring (A) having ring (a) aromatic selected from optionally substituted benzo and pyrido and ring (b) non-aromatic and in which  $Y^2$  has 3-5 atoms including a

heteroatom bonded to  $X^5$  selected from NR<sup>13</sup>, O or S and NHCO bonded via N to  $X^3$ , or O bonded to  $X^3$ .

16. (New) A compound or salt according to claim 1, wherein R<sup>12</sup> is:

3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazin-6-yl,

3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]oxazin-6-yl, or

2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl.

17. (New) A compound according to claim 1, wherein the compound is:

 $6-(\{2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethylamino\}$  methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;

 $6-(\{2-[1-(3-chloro-6-methoxy-[1,5]naphthyridin-4-yl)phenyl] \\ ethylamino\}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;$ 

6-({2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl] ethylamino} methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;

 $6-(\{2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl] ethylamino\}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one; \\$ 

6-{[(2-{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl) amino]methyl}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; or

6-{[(2-{4-[7-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl} ethyl)amino]methyl}-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one; or

a pharmaceutically acceptable salt thereof.

18. (New) A compound according to claim 1, wherein the compound is:

 $6-(\{2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethylamino\}\ methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;$ 

 $6-(\{2-[1-(3-chloro-6-methoxy-[1,5]naphthyridin-4-yl)phenyl] \\ ethylamino\}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;$ 

 $6-({2-[4-(6-methoxynaphthyridin-4-yl)piperazin-1-yl]}$  ethylamino} methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;

 $6-(\{2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl] ethylamino\}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one; \\$ 

 $N-(2-\{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl\}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;$ 

N-methyl-N-(2-{1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl} ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

N-methyl-N-(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxamide;

6-{[(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]hexahydro-1H-1,4-diazepin-1-yl}ethyl)amino]methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;

 $6-\{[(2-\{(1R,4R)-5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2,5-diazabicyclo [2.2.1]hept-2-yl\}ethyl)amino]methyl\}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;$ 

6-[({1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}amino) methyl]-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;

6-{[(2-{4-hydroxy-1-[6-(methyloxy)-1,5-naphthyridin-4-yl]-4-piperidinyl}ethyl) amino]methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; or

6-{[(2-{4-[7-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl} ethyl) amino]methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; or

a pharmaceutically acceptable salt thereof.

- 19. (New) A compound according to claim 1, wherein the compound is:
- (2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[1-(6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethyl}amine;

{2-[1-(3-chloro-6-methoxynaphthyridin-4-yl)piperidin-4-yl]ethyl}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine;

(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)-{2-[4-(6-methoxynaphthyridin-4-yl)piperizin-1-yl]ethyl}amine;

 $\{2-[4-(3-chloro-6-methoxynaphthyridin-4-yl)piperazin-1-yl]ethyl\}-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-ylmethyl)amine; or$ 

7-{[(2-{4-[6-(methyloxy)-1,5-naphthyridin-4-yl]-1-piperazinyl}ethyl) oxy] methyl}-2,3-dihydro[1,4]dioxino[2,3-c]pyridine, or

a pharmaceutically acceptable salt thereof.

- 20. (New) A pharmaceutical composition, comprising a compound or salt according to claim 10 and a pharmaceutically acceptable carrier.
- 21. (New) A method of treating bacterial infections in a human, which comprises administering to a human in need thereof an effective amount of a compound or salt according to claim 10.